Novo Holdings has joined the early-stage consortium of Praxis Precision, a gene therapy business co-founded by faculty from Columbia and Melbourne universities.

Praxis Precision, a US-based gene therapy developer targeting neurological and psychiatric disorders, emerged from stealth on Monday with more than $100m raised to date from investors co-led by pharmaceutical firm Novo Holdings. The consortium is also co-led by Praxis’s founding investor Blackstone Life Sciences, which participated through its Clarus subsidiary, as well as venture capital…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.